NASDAQ · LXRX
Healthcare · Biotechnology
$2.05
Down-$0.03 (-1.23%)
Updated Sep 21, 2026, 3:56 PM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
LXRX closed at $2.05 after 19 trading sessions, down 11.64% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $2.04 | $2.06 | $1.99 | $2.05 | 7.46M |
| Sep 17, 2026 | $2.05 | $2.11 | $2.015 | $2.035 | 2.24M |
| Sep 16, 2026 | $2.01 | $2.055 | $2.00 | $2.02 | 2.15M |
| Sep 15, 2026 | $1.98 | $2.02 | $1.885 | $2.01 | 2.51M |
| Sep 14, 2026 | $1.97 | $2.01 | $1.935 | $1.98 | 1.77M |
| Sep 11, 2026 | $2.05 | $2.06 | $1.95 | $2.00 | 3.73M |
| Sep 10, 2026 | $2.11 | $2.14 | $2.01 | $2.02 | 2.94M |
| Sep 9, 2026 | $2.21 | $2.23 | $2.13 | $2.15 | 2.2M |
| Sep 8, 2026 | $2.22 | $2.25 | $2.19 | $2.23 | 1.66M |
| Sep 4, 2026 | $2.25 | $2.255 | $2.215 | $2.24 | 1.04M |
| Sep 3, 2026 | $2.25 | $2.27 | $2.23 | $2.26 | 1.51M |
| Sep 2, 2026 | $2.21 | $2.265 | $2.19 | $2.24 | 2.34M |
| Sep 1, 2026 | $2.24 | $2.2689 | $2.17 | $2.19 | 1.99M |
| Aug 31, 2026 | $2.27 | $2.29 | $2.19 | $2.25 | 6.65M |
| Aug 28, 2026 | $2.30 | $2.32 | $2.26 | $2.29 | 2.68M |
| Aug 27, 2026 | $2.30 | $2.339 | $2.295 | $2.32 | 1.62M |
| Aug 26, 2026 | $2.32 | $2.3488 | $2.28 | $2.31 | 1.2M |
| Aug 25, 2026 | $2.35 | $2.365 | $2.30 | $2.34 | 1.82M |
| Aug 24, 2026 | $2.32 | $2.35 | $2.295 | $2.32 | 1.68M |
The latest Smart Investors Daily articles mentioning LXRX.
LXRX research
Company profile and research snapshot.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 11, 2026 | Citigroup | Buy | — |
| Mar 23, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 10, 2026 | Citigroup | Buy | — |
| Mar 5, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 2, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 9, 2026
Lexicon Pharmaceuticals, Inc. (LXRX) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 11:20 AM EDTCompany ParticipantsMichael Exton - CEO...
Yahoo · Sep 1, 2026
THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management will present at three upcoming investor conferences taking place in New York, NY: Citi 2026 Biopharma Back to School Conference September 9, 2026, 11:20–11:55 AM (Eastern Time) 2026 Cantor Global Healthcare ConferenceSeptember 10, 2026, 3:20–3:50 PM (Eastern Time) H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 14, 2026, 9:00–9:30 AM (Eas
Yahoo · Aug 31, 2026
Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart FailureTHE WOODLANDS, Texas, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced results from a post hoc analysis of the Phase 3 SOLOIST-WHF trial evaluating the efficacy and safety of sotagliflozin across the spectrum of baseline systolic blood pressure in patients recently hospitalized for worsening heart failure. The data, which were presented yesterday at ESC Congres
SeekingAlpha · Aug 19, 2026
Lexicon Pharmaceuticals (LXRX) is nearing multiple potential value-transforming events for sotagliflozin, and the shares have been strong since my last...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LXRX.
